Nevro to Present at 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO), a leader in chronic pain solutions, announced that D. Keith Grossman, Chairman and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 4:30 PM ET. This event can be accessed via a live webcast available in the Investors section of Nevro's website. Nevro specializes in innovative medical devices, including the Senza spinal cord stimulation system, known for its HF10 therapy that significantly reduces opioid dependency in over 65% of patients.

REDWOOD CITY, Calif., Dec. 15, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the 39^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 4:30 pm Eastern Time / 1:30 pm Pacific Time.

A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com. 

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10^® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  julie.dewey@nevro.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-present-at-39th-annual-jp-morgan-healthcare-conference-on-tuesday-january-12-2021-301193447.html

SOURCE Nevro Corp.

FAQ

When is Nevro presenting at the J.P. Morgan Healthcare Conference?

Nevro will present on January 12, 2021, at 4:30 PM ET.

Who is presenting for Nevro at the conference?

D. Keith Grossman, Chairman and CEO of Nevro, will present.

Where can I watch Nevro's conference presentation?

You can watch the presentation via a live webcast on Nevro's website.

What is the focus of Nevro's product offering?

Nevro focuses on innovative solutions for chronic pain treatment, particularly through spinal cord stimulation.

How effective is Nevro's HF10 therapy?

HF10 therapy has shown to reduce or eliminate opioid use in over 65% of patients in clinical studies.